Pulmonary Hypertension (PH) Withdrawn Phase 4 Trials for Ambrisentan (DB06403)

Also known as: Hypertension, Pulmonary / Pulmonary; Hypertension / Pulmonary hypertension / Hypertension Pulmonary / Pulmonary hypertensions / Pulmonary hypertension NOS

IndicationStatusPhase
DBCOND0051788 (Pulmonary Hypertension (PH))Withdrawn4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03309592Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary HypertensionTreatment